Breaking Finance News

A statement released earlier today by Zacks Investment Research about Supernus Pharmaceuticals Inc (NASDAQ:SUPN) raises the target price to $24.00

Yesterday Supernus Pharmaceuticals Inc (NASDAQ:SUPN) traded -0.23% lower at $21.60. The company’s 50-day moving average is $21.24 and its 200-day moving average is $21.37. The last stock close price is up 1.06% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 33,969 shares of the stock were exchanged, down from an average trading volume of 684,552

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had its target price raised to $24.00 by Zacks Investment Research in a report released Tuesday November 29, 2016. The new target price indicates a possible upside of 0.11% based on the company's last stock close price.

See Chart Below

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Supernus Pharmaceuticals Inc has a 52 week low of $9.51 and a 52 week high of $26.84 with a P/E ratio of 44.08 The company’s market cap is currently $0.

About Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.